Lymphokine gene therapy of cancer
US5681562A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 9, 1994 |
| Grant date | Oct 28, 1997 |
| Priority date | — |
| Expiry date | Dec 9, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.